

EQUINE DRUG AND METABOLITE STANDARDS

by

**Wojciech Karpiesiuk, Fritz Lehner, W. Edward Woods
and Thomas Tobin**

**Maxwell H. Gluck Equine Research Center
Department of Veterinary Science
University of Kentucky
Lexington, KY 40546**

EQUINE DRUG METABOLITES AND STANDARDS

The equine drug metabolites and standards listed in this document were synthesized and characterized by Dr. Wojciech Karpiesiuk of the Equine Pharmacology and Experimental Therapeutics Program in the Maxwell H. Gluck Equine Research Center, Department of Veterinary Science, College of Agriculture, University of Kentucky. These specification sheets present a total ion chromatogram of the specific substance, along with a full scan mass spectrum developed under appropriate mass spectral conditions. The mass spectral analyses were largely performed by Dr. Fritz Lehner. For all of these compounds ^1H -nmr spectra, (200MHz), ^{13}C NMR spectra (50 MHz), FT-IR spectra are available and, for many of them, DSC thermograms. Stability studies relevant to standard laboratory procedures are available for some of these agents and were carried out by Mr. Ed Woods.

Synthesis of these agents was made possible by support from the Florida Division of the Horsemen's Benevolent and Protective Association, The National Horsemen's Benevolent and Protective Association and the Kentucky Equine Drug Council and the Kentucky Racing Commission.

A bibliography of research papers based on these metabolites or relevant to these metabolites is presented in the appendix.

This communication is publication # 252 from the Equine Pharmacology and Experimental Therapeutics Program in the Maxwell H. Gluck Equine Research Center, Department of Veterinary Science, University of Kentucky.

Published as Kentucky Agricultural Experiment Station Article # xx-xxx-xxx with the approval of the Dean and Director, College of Agriculture and the Kentucky Agricultural Experiment Station.

EQUINE DRUG AND METABOLITE STANDARDS

by

Wojciech Karpiesnik


Fritz Lehner

Thomas Tobin

Maxwell H. Gluck Equine Center, University of Kentucky, Lexington KY 40546

No.	DRUG	METABOLITE/ DEUTERATED STANDARD	REMARKS
1.	LIDOCAINE	3-HYDROXYLIDOCAINE	metabolite
2.	MEPTIVACAINE	3-HYDROXYMEPTIVACAINE	metabolite
3.	BUPIVACAINE	3-HYDROXYBUPIVACAINE	metabolite
4.	ROPIVACAINE	3-HYDROXYROPIVACAINE (NPRP)	metabolite
5.	PYRILAMINE	O-DESMETHYLPYRILAMINE	metabolite
6.	ACEPROMAZINE	2-(1-HYDROXYETHYL)PROMAZINE SULFOXIDE	metabolite
7.	ACEPROMAZINE	(1-HYDROXYETHYL)PROMAZINE (un-crystallized)	metabolite
8.	PROMETHAZINE	PROMETHAZINE SULFOXIDE	metabolite
9.	PROMAZINE	3-OH-PROMAZINE	metabolite
10.	PROPIONYLPROMAZINE	2-(1-HYDROXYPROPYL)PROMAZINE SULFOXIDE	metabolite
11.	PROPRANOLOL	4-OH-PROPRANOLOL	metabolite
12.	MAZINDOL	2-(2-AMINOETHYL)-3-(4-CHLOROPHE- NYL)-3-HYDROXY-2,3-DIHYDRO-ISO- INDOL-1-ONE	metabolite
13.	TRIPLENNAMINE	3-OH-TRIPLENNAMINE	drug derivative
14.	PHENYLEBUTAZONE	PHENYLEBUTAZONE-D ₃	deuterated standard
15.	PROCAINE	PROCAINE-D ₁₀	deuterated standard
16.	FUROSEMIDE	FUROSEMIDE-D ₃	deuterated standard

EQUINE METABOLITE STANDARD



3-HYDROXYLIDOCAINE (lidocaine metabolite)

CAS Name: acetamide, 2-diethylamino-N-(3-hydroxy-2,6-dimethylphenyl)-

CAS No.: [34604-55-2]

Molecular Formula: $C_{14}H_{22}N_2O_2$

Molecular Mass: 250.34 g/mol

LOT # LID 0995

Date: 10-10-95

Properties: colorless crystals (from acetone)

Solubility: soluble in methanol

Estimated Purity: 98 %


Melting point: 205-206 °C

Storage: store below room temperature


Quantity: 1 mg

GC/MS data: column 30 m x 0.25 mm x 0.25 µm HP 5-MS; temperature: 70-230 °C at 20 °C/min; flow rate 1 mL/min He; injection: splitless

Abundance




Abundance



¹H-NMR spectrum (300 MHz, CDCl₃), ¹³C-NMR spectrum (50 MHz, DMSO-d₆), FT-IR spectrum and DSC thermogram available upon request.

EQUINE METABOLITE STANDARD



3-HYDROXYMEPIVACAINE (mepivacaine metabolite)

CAS Name: 2-piperidinecarboxamide, N-(3-hydroxy-2,6-dimethylphenyl)-1-methyl-

CAS No.: [37055-90-6]

Molecular Formula: $C_{15}H_{23}N_2O_2$

Molecular Mass: 262.35 g/mol

LOT # MEP 0296

Date: 02-26-96

Properties: white powder

Solubility: soluble in methanol



Estimated Purity: 98 %

Melting point: 194-197 °C

Storage: store below room temperature


Quantity: 1 mg

GC/MS data: column 30 m x 0.25 mm x 0.25 µm HP 3042; temperature: 70-200 °C at 20 °C/min; flow rate 1 mL/min He; injection: splitless



¹H-NMR spectrum (200 MHz, CDCl₃), ¹³C-NMR spectrum (50 MHz, CDCl₃), FT-IR spectrum and DSC thermogram available upon request

EQUINE METABOLITE STANDARD



3-HYDROXYBUPIVACAINE (bupivacaine metabolite)

CAS Name: 2-piperidinecarboxamide, 1-butyl-N-(3-hydroxy-2,6-dimethylphenyl)-

CAS No.: [51989-46-9]

Molecular Formula: $C_{19}H_{25}N_2O_2$

Molecular Mass: 304.43 g/mol

LOT # BUP 0597

Date: 05-20-97

Properties: white crystals

Solubility: soluble in methanol

Estimated Purity: 97 %


Melting point: 194-195 °C

Storage: store below room temperature


Quantity: 1 mg

GC/MS data: column 30 m x 0.25 mm ID 0.25 µm HP 5-MS; temperature: 70-230 °C at 20 °C/min; flow rate 1 mL/min He; Injection: splitless

Abundance




Abundance



¹H-NMR spectrum (200 MHz), ¹³C-NMR spectrum (50 MHz), FT-IR spectrum and DSC thermogram available upon request.

EQUINE METABOLITE STANDARD



O-DESMETHYLPYRILAMINE (pyrilamine metabolite)

CAS Name: phenol, 4-[[[2-(dimethylamino)ethyl]-2-pyridinylamino]methyl]-

CAS No.: [57830-29-2]

Molecular Formula: $C_{14}H_{21}N_3O$

Molecular Mass: 271.36 g/mol

LQT # DMP 0596

Date: 06-06-96

Properties: white powder

Solubility: soluble in methanol



Estimated Purity: 97 %

Melting point: 119-120°C

Storage: store below room temperature


Quantity: 1 mg

GC/MS data: column 30 m H 0.25 mm H 0.25 μ m HP 5-MS; temperature: 70-250°C at 20 °C/min; flow rate 1 mL/min He; injection: splitless



¹H-NMR spectrum (200 MHz, CDCl₃), ¹³C-NMR spectrum (50 MHz, CDCl₃), FT-IR spectrum and DSC thermogram available upon request

EQUINE METABOLITE STANDARD



2-(1-HYDROXYETHYL)PROMAZINE SULFOXIDE (HEPS, acepromazine metabolite)

CAS Name: 10H-phenothiazine-2-methanol, 10-[3-(dimethylamino)-propyl]- α -methyl-5-oxide-

CAS No.: [73644-42-5]

Molecular Formula: $C_{19}H_{24}N_2O_2S$

Molecular Mass: 344.47 g/mol

LOT # HEPS 0796

Date: 07-30-96

Properties: white powder.



Solubility: soluble in methanol

Estimated Purity: >97 %

Storage: store below room temperature


Quantity: 1 mg

GC/MS data: column 30 m x 0.25 mm x 0.25 μ m HP 5MS; temperature: 70-280°C at 20 °C/min; flow rate 1 mL/min He; Injection: splitless



1H -NMR spectrum (200 MHz, $CDCl_3$), ^{13}C -NMR spectrum (50 MHz, $CDCl_3$) and FT-IR spectrum available upon request

EQUINE METABOLITE STANDARD



PROMETHAZINE SULFOXIDE (promethazine metabolite)

CAS Name: 10*H*-phenothiazine-10-ethanamine, *N,N*, α -trimethyl-5-oxide-

CAS No.: [7640-51-9]

Molecular Formula: $C_{17}H_{23}N_2OS$

Molecular Mass: 300.42 g/mol

LOT # PMSO 0796

Date: 11-09-95

Properties: colorless crystals (ethyl ether - hexane)

Melting point: 118-120 °C



Solubility: soluble in methanol

Storage: store below room temperature

Estimated Purity: 99 %


Quantity: 1 mg

GC/MS data: column 30 m $\times$ 0.25 mm $\times$ 0.25 μ m HP 5MS; temperature: 70-230 °C at 20 °C/min; flow rate 1 mL/min He; Injection: splitless



¹H-NMR spectrum (200 MHz, CDCl₃), ¹³C-NMR spectrum (50 MHz, CDCl₃) and FT-IR spectrum available upon request

EQUINE METABOLITE STANDARD



3-HYDROXYPROMAZINE (promazine metabolite)

CAS Name: 10*H*-phenothiazine-3-ol, 10-[3-(dimethylamino)propyl]-

CAS No.: [316-85-8]

Molecular Formula: $C_{27}H_{33}N_2OS$

Molecular Mass: 300.42 g/mol

LOT # 3HPM 1196

Date: 10-07-97

Properties: very sensitive to light



Solubility: soluble in methanol

Estimated Purity: >97 %

Storage: store below room temperature in a dark place


Quantity: 1 mg

GC/MS data: column 30 m x 0.25 mm x 0.25 μ m HP 288; temperature: 70-200°C at 30°C/min; flow rate 1 mL/min He; injection: splitless



¹H-NMR spectrum (200 MHz, CDCl₃), ¹³C-NMR spectrum (50 MHz, CDCl₃) and FT-IR spectrum available upon request

EQUINE METABOLITE STANDARD



4-HYDROXYPROPRANOLOL (propranolol metabolite)

CAS Name: 1-naphthalenol, 4-[2-hydroxy-3-[(1-methylethyl)-amino]propoxy]-

CAS No.: [10476-53-6]

Molecular Formula: $C_{16}H_{21}NO_2$

Molecular Mass: 275.35 g/mol

LOT # HPR 1296

Date: 12-16-96

Properties: brownish powder

Solubility: soluble in methanol



Estimated Purity: 99 %

Melting point: 137-141 °C (decomp.)

Storage: store below room temperature


Quantity: 1 mg

GC/MS data: column 30 m x 0.25 mm x 0.25 µm HP 5-MS; temperature: 70-250 °C at 20 °C/min; flow rate 1 mL/min He; injection: splitless



¹H-NMR spectrum (200 MHz, DMSO-d₆), ¹³C-NMR spectrum (50 MHz, DMSO-d₆), FT-IR spectrum (KBr) and DSC thermogram available upon request.

EQUINE METABOLITE STANDARD



MAZINDOL METABOLITE

CAS Name: 2H-isindol-3-ol, 2-(2-aminopropyl)-3-(p-chlorophenyl)-1,3-dihydro-1-oxo-

CAS No.: [5983-84-6]

Molecular Formula: $C_{16}H_{15}ClN_2O_2$

Molecular Mass: 302.76 g/mol

LOT # MAZ 0196

Date: 01-23-96

Properties: white powder

Solubility: soluble in methanol



Estimated Purity: 98 %

Melting point: 171-172 °C

Storage: store below room temperature


Quantity: 1 mg

GC/MS data: column 30 m x 0.25 mm x 0.25 µm HP 5-MS; temperature: 70-250°C at 20 °C/min; flow rate 1 mL/min He; injection: splitless



¹H-NMR spectrum (200 MHz, CDCl₃), ¹³C-NMR spectrum (50 MHz, CDCl₃), FT-IR spectrum and DSC thermogram available upon request

EQUINE MEDICATION DERIVATIVE



3-OH-TRIPLEPPAMINE

CAS Name: phenol, 3-[[[2-(dimethylamino)ethyl]-2-pyridinylamino]methyl]-

CAS No.: [not registered as yet]

Molecular Formula: $C_{16}H_{21}N_3O$

Molecular Mass: 271.36 g/mol

LOT # TPA 0596

Date: 05-10-96

Properties: white powder

Solubility: soluble in methanol



Estimated Purity: 99 %

Melting point: 126-127 °C

Storage: store below room temperature


Quantity: 1 mg

GC/MS data: column 30 m x 0.25 mm x 0.25 µm HP 5MS; temperature: 70-250 °C at 20 °C/min; flow rate 1 mL/min He; injection: splitless



1H -NMR spectrum (200 MHz, $CDCl_3$), ^{13}C -NMR spectrum (50 MHz, $CDCl_3$), FT-IR spectrum and DSC thermogram available upon request.

EQUINE MEDICATION DEUTERATED STANDARD



PHENYLBUTAZONE-D₉

Name: 3,5-Pyrazolidinedione, 4-butyl-d₉-1,2-diphenyl-

CAS No.: [not registered]

Molecular Formula: C₁₉H₁₃D₉N₂O₂

Molecular Mass: 317.43 g/mol

LOT # PB-D 0396

Date: 08-16-96

Properties: white crystals

Melting point: 105 °C



Solubility: soluble in methanol

Storage: store below room temperature

Estimated Purity: 99 %


Quantity: 1 mg

GC/MS data: column 30 m x 0.25 mm x 0.25 µm HP 5-MS; temperature: 70-250°C at 20 °C/min; flow rate 1 mL/min He; injection: splitless



¹H-NMR spectrum (200 MHz, CDCl₃), ¹³C-NMR spectrum (50 MHz, CDCl₃), FT-IR spectrum (KBr) and DSC thermogram available upon request.

EQUINE MEDICATION DEUTERATED STANDARD



PROCAINE-D₁₀ HYDROCHLORIDE

Name: Benzoic acid, 4-amino-, 2-(diethyl-d₁₀-amino)ethyl ester, monohydrochloride

CAS No.: [not registered]

Molecular Formula: C₁₃H₁₈D₁₀N₂O₂•HCl

Molecular Mass: 282.84 g/mol (free base 246.37 g/mol)

LOT # PROC-D 0997

Date: 09-23-96

Properties: white crystals

Solubility: soluble in methanol



Estimated Purity: 99 %

Melting point: 153-154 °C (from ethanol)

Storage: store below room temperature


Quantity: 1 mg

GC/MS data: column 30 m x 0.25 mm x 0.25 µm HP 5MS; temperature: 70-250 °C at 20 °C/min; flow rate 1 mL/min He; Injection: splitless



¹H-NMR spectrum (200 MHz), FT-IR spectrum and DSC thermogram available upon request

EQUINE MEDICATION DEUTERATED STANDARD



FUROSEMIDE-D₃

Name: Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-[(2-furanyl-d₃-methyl-d₃)amino]-

CAS No.: [not registered]

Molecular Formula: C₁₂H₆D₃ClN₂O₅S

Molecular Mass: 335.78 g/mol

LOT # FUR-D 0997

Date: 09-23-96

Properties: white crystals

Solubility: soluble in methanol



Estimated Purity: 85 % D₃ + 14 % D₄

Melting point: 207-208 °C (from ethanol-water)

Storage: store below room temperature

Quantity: 1 mg

GC/MS data: column 30 m x 0.25 mm x 0.25 µm HP 5-MS; temperature: 70-200 °C at 20 °C/min; flow rate 1 ml/min He; injection: splitless



¹H-NMR spectrum (200 MHz, DMSO-d₆), ¹³C-NMR spectrum (50 MHz, DMSO-d₆), FT-IR spectrum and DSC thermogram available upon request.

BIBLIOGRAPHY

1) Lidocaine (metabolite: 3-hydroxylidocaine)

Thomas, J. and Meffin P., "Aromatic hydroxylation of lidocaine and mepivacaine in rats and humans", *J. Med. Chem.*, 15 (1972), 1046-1049.

2) Mepivacaine (metabolite: 3-hydroxymepivacaine)

Thomas, J. and Meffin P., "Aromatic hydroxylation of lidocaine and mepivacaine in rats and humans", *J. Med. Chem.*, 15 (1972), 1046-1049.

3) Bupivacaine (metabolite: 3-hydroxybupivacaine) (only analytical data)

Bouche, R. and Lhoest, G., "Isolation and identification by mass spectrometry of metabolites of bupivacaine", *Pharm. Acta Helv.*, 51 (1976), 223-225

4) Ropivacaine

There is no data about synthesis of 3-hydroxyropivacaine in the literature

5) Acepromazine [metabolite: 2-(1-hydroxyethyl)promazine sulfoxide - HEPS]

Dewey, E. A.; Maylin, G.A.; Ebel, J. G.; Henion, J. D., "The metabolism of promazine and acetylpromazine in the horse", *Drug Metab. Dispos.* 1981, 9(1), 30-36.

6) Propranolol (metabolite: 4-hydroxypropranolol)

Oatis, J. E.; Russell, M. P.; Knapp, D. R.; Walle, T., "Ring-hydroxylated propranolol: synthesis and β -receptor antagonist and vasodilating activities of the seven isomers", *J. Med. Chem.* 1981, 24, 309-314.

7) Promethazine (metabolite: promethazine sulfoxide)

Sackett, P. H.; Mayausky, J. S.; Smith, T.; Kahuz, S; McCreery, R. L.; *J. Med. Chem.* 24 (1981) 1342-1347.

8) Promazine (metabolite: 3-hydroxypromazine)

8.1) Dewey, E. A.; Maylin, G.A.; Ebel, J. G.; Henion, J. D., "The metabolism of promazine and acetylpromazine in the horse", *Drug Metab. Dispos.* 1981, 9(1), 30-36.

8.2) Craig, J. Cymerman; Kray, L. R., "Synthesis, characterization and properties of phenolic derivatives of some phenothiazines", *Agressologie* 1968, 9 (1), 55-58.

9) Analytical/Pharmacological References:

- 9) Harkins, J.D., S. Stanley, G.D. Mundy, R.A. Sams, W.E. Woods, and T. Tobin. A review of the pharmacology, pharmacokinetics, and regulatory control in the US of local anesthetics in the horse. *J.Vet.Pharmacol.Therap.* 18, 397-406, 1995
- 10) Harkins, J.D., G.D. Mundy, S. Stanley, W.E. Woods, W.A. Rees, K.N. Thompson, and T. Tobin. Determination of highest no-effect doses (HNEDs) for local anesthetic responses to procaine, cocaine, bupivacaine, and benzocaine. *Eq.Vet.J.* 28, 30-37, 1996.
- 11) Harkins, J.D., G.D. Mundy, S. Stanley, W.E. Woods, J. Boyles, R.A. Arthur, R.A. Sams, and T. Tobin. Regulatory significance of procaine residues in plasma and urine samples: A preliminary communication. *Eq.Vet.J.* 28, 121-125, 1996.
- 12) Harkins, J.D., Mundy, G.D., Stanley, S.D., Sams, R.A., and Tobin, T. Lack of local anesthetic efficacy of Sarapin in the abaxial sesamoid block model. *J.Vet.Pharmacol.Therap.* 20, 229-232, 1997.
- 13) Harkins, J.D., Mundy, G.D., Woods, W.E., Lehner, A., Karpiesiuk W., Rees, W.A., Dirikolu, L., Bass, S., Carter, W.G., Boyles, J., and Tobin, T. Lidocaine: Pharmacological effects and their relationship to analytical findings (Submitted to *J. Vet. Pharmacol. Therap.*)
- 14) Harkins, J.D., Mundy, G.D., Karpiesiuk W., Woods, W.E., Lehner, A., Rees, W.A., Dirikolu, L., Bass, S., Carter, W.G., Boyles, J., and Tobin, T. Mepivacaine: Its pharmacological effects and their relationship to analytical findings in the horse (Submitted to *J. Vet. Pharmacol. Therap.*)
- 15) Harkins, J.D., Karpiesiuk W., Woods, W.E., Lehner, A., Rees, W.A., Dirikolu, L., Bass, S., Carter, W.G., Boyles, J., and Tobin, T. Bupivacaine: Its pharmacological effects and their relationship to analytical findings in the horse (Submitted to *J. Vet. Pharmacol. Therap.*)
- 16) Harkins, J.D., Karpiesiuk W., Woods, W.E., Lehner, A., Rees, W.A., Dirikolu, L., Bass, S., Carter, W.G., Boyles, J., and Tobin, T. Ropivacaine: Its pharmacological effects and analytical detection in the horse (In draft)